US2009238803A1PendingUtilityA1

Human cord blood derived unrestricted somatic stem cells (ussc)

56
Assignee: KOURION THERAPEUTICS GMBHPriority: Nov 3, 2000Filed: Apr 2, 2009Published: Sep 24, 2009
Est. expiryNov 3, 2020(expired)· nominal 20-yr term from priority
Inventors:Peter Wernet
A61P 7/00A61P 41/00A61P 9/00A61P 43/00A61P 3/10A61P 25/00A61P 25/16A61P 1/16C12N 5/0607A61K 35/51A61P 1/00A61K 35/545A61P 21/00A61K 35/50
56
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A composition in human cord and placental blood which comprises unrestricted somatic stem cells is described here which can be amplified in vitro to large quantities sufficient for medical applications as regenerative medicines. Initiation and maintenance as well as ex vivo expansion protocols of such stem cells from cord blood is described. Furthermore, it is shown that from these cells employing varying differentiation induction protocols distinct lineage progenitors for hematopoiesis and endothel, as well as mesenchymal progenitors for muscle bone, cartilage and fat as well as neural progenitors can be cultured and expanded for use in regenerative medicine.

Claims

exact text as granted — not AI-modified
1 . An isolated unrestricted somatic stem cell (USSC) prepared from human umbilical cord blood or placental blood, wherein said USSC is negative for the CD14 and CD45 antigens and positive for the CD13 and CD29 and lacks expression of hyaluronan synthase. 
     
     
         2 . A medicament comprising the isolated cell of  claim 1  and a pharmaceutically acceptable carrier. 
     
     
         3 . A method for treating a disease other than a disease of connective tissue, bone, or cartilage in a human patient, said method comprising administering to said patient an unrestricted somatic stem cell (USSC), wherein said USSC is negative for the CD14 and CD45 antigens and positive for the CD13 and CD29 and lacks expression of hyaluronan synthase. 
     
     
         4 . The method of  claim 3 , wherein said USSC is isolated from umbilical cord blood or placental blood. 
     
     
         5 . The method of  claim 3 , wherein said disease is a vascular disease. 
     
     
         6 . The method of  claim 3 , wherein said disease is a hepatic disease. 
     
     
         7 . The method of  claim 3 , wherein said disease is type 1 diabetes. 
     
     
         8 . The method of  claim 3 , wherein said disease is a neural disease. 
     
     
         9 . The method of  claim 3 , wherein said disease is Parkinson's disease. 
     
     
         10 . The method of  claim 3 , wherein said disease is a hematological disease.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.